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may be more common than many doctors realise or may be missed at
first presentation. The series advisers are Anthony Harnden, university
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University of Oxford, and Richard Lehman, general practitioner, Banbury.
To suggest a topic for this series, please email us at
easilymissed@bmj.com.
A 72 year old recently widowed man presents to his general
practitioner with vague symptoms, including fatigue. Nothing
is found on examination, but his haemoglobin concentration is
114 g/L (range 140-180 g/L) with a hypochromic, normocytic
picture and serum ferritin 75 ng/mL (30-336 ng/mL). As his
diet has been poor since his wife died, he was treated with
ferrous sulphate, which was associated with a small
improvement in his fatigue and haemoglobin level. Six months
later he presented with intestinal obstruction, which was
subsequently found to be due to a carcinoma of the colon.
Surgically, the colon and rectum are distinct, but for the purposes
of this diagnostic article, they have been merged.
Why is colorectal cancer missed?
Many colorectal cancers are diagnosed easily and quickly and
times to diagnosis (generally measured as the diagnostic interval
from first presentation to primary care up to diagnosis) are less
than three months—particularly for patients whose clinical
features meet the referral guidelines of the National Institute
for Health and Clinical Excellence for suspected cancer.4
Symptoms include diarrhoea or rectal bleeding for six weeks
in patients aged more than 60, or for patients older than 40 if
both symptoms are present; rectal or abdominal masses or iron
deficiency anaemia with haemoglobin concentrations less than
110 g/L in men and less than 100 g/L in women. However,
about half of patients do not meet this guidance and have longer
diagnostic intervals.5Mortality from colorectal cancer is strongly
related to the first symptom, withmildly anaemic patients having
the worst prognosis; adjusted proportional hazard ratio compared
with all patients with colorectal cancer of 1.9 (95% confidence
interval 1.1 to 2.7).6 Audits from several countries suggest that
about a third of patients experience diagnostic delays, with
anaemia, rectal bleeding, and abdominal pain being the most
usual missed opportunities.7-9These three symptoms are common
in primary care, with alternative diagnoses to cancer more likely.
Furthermore, NICE guidance recommends urgent investigation
only for pronounced iron deficiency anaemia (haemoglobin
<110 g/L in men, and <100 g/L in women) or for persistent
rectal bleeding (six weeks, unless accompanied by diarrhoea).4
Additionally, the possibility of cancer may be dismissed in
patients with rectal bleeding and haemorrhoids.
Why does this matter?
A complex J-shaped relation exists between the diagnostic
interval and mortality.10 The best prognosis is for patients with
an interval of around one month, probably reflecting the timely
diagnosis of non-emergency patients. The high mortality with
shorter intervals probably represents obviously ill patients with
an inherently poor prognosis (including emergency admissions).
The prognosis steadily worsens with increasing intervals
thereafter. Expedited diagnosis may allow identification at an
earlier stage, or may obviate emergency admission.
How is colorectal cancer diagnosed?
The rest of this article assumes patients whomeet current NICE
guidance are investigated, and concentrates on presentations
that do not meet NICE guidelines.4 It does not concern factors
before presentation to medical care: there can be major delays
from patients not recognising that their symptoms are
important.11 We found no literature suggesting that colorectal
cancers in patients under 40 present differently from those in
older patients. Similarly, we found no primary care study of
colorectal cancer symptoms in patients with inflammatory bowel
disease.
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Search strategy
WH and colleagues recently performed a systematic review of primary care symptoms of colorectal cancer.1 This was supplemented by
specific searches on missed or delayed diagnoses, plus searches on young people, irritable bowel syndrome, and inflammatory bowel
disease. No randomised controlled trials have been reported on the selection of patients for investigation, so most of the quoted studies are
large cohort studies, often using national primary care databases. Cited studies can be assumed to be of this nature unless specifically
stated otherwise.
How common is colorectal cancer?
• Colorectal cancer is the third most prevalent cancer in the United Kingdom, the incidence increasing with age, and it is slightly more
common in men
• More than 41 000 new cases of colorectal cancer are diagnosed annually in the United Kingdom, with the median age at diagnosis
72 years, although 6% occur below the age of 402
• Screening identifies a few patients with cancers; the remainder present with symptoms, with around a quarter presenting as an
emergency3
• A full time general practitioner will have around one patient with a new diagnosis of colorectal cancer each year
Anaemia
Around a third of patients with colorectal cancer in a hospital
case series had anaemia but of insufficient severity to meet
current NICE guidance, as in our hypothetical case.12 For those
meeting the guidance, the estimated risk of cancer in a large
UK case-control study was 13.3% for men and 7.7% for
women.13 The most common measure of iron stores is serum
ferritin level, with values below 44.9-67.4 pmol/L (20-30
ng/mL) being regarded as abnormal (individual laboratories
have differing ranges). However, in anaemic patients
investigated by colonoscopy, those with ferritin levels below
112.4 pmol/L and 112.4-222.5 pmol/L had a similar risk of
cancer.14 Together, this suggests that current guidance is too
restrictive. In men aged more than 60 with iron deficiency
anaemia, the risk of cancer with a haemoglobin concentration
of 110-119 g/L is over 4%; even haemoglobin values of 120-129
g/L represent risks of 3.9% in the 70-79 year age group.13 The
values for women reflect their lower normal haemoglobin range:
even so, the risk of cancer in women with haemoglobin
concentrations of 110-119 g/L is more than 2.4%. Raising the
haemoglobin threshold to allow investigation at such levels
would require more colonoscopies but would be in keeping with
the threshold risk values used by NICE for other colorectal
cancer symptom patterns.4
Abdominal pain
Abdominal pain is themost typical symptom of colorectal cancer
(alongside rectal bleeding) but it has a low positive predictive
value for colorectal cancer of 1.1%, although this increases to
3.0% if abdominal pain is reported again to primary care.15When
other symptoms, such as diarrhoea or loss of weight, are present,
the risk is higher, although rarely above 3%.15 Few patients with
abdominal pain are investigated for possible colorectal cancer
at their first presentation. One classic misdiagnosis is irritable
bowel syndrome. There is no causative association between
irritable bowel syndrome and colorectal cancer; however, around
1% of patients with an initial diagnosis of irritable bowel
syndrome prove to have colorectal cancer.16 All patients with a
new diagnosis of irritable bowel syndrome warrant clinical
review to confirm that their symptoms are stable and responding
to management (diagnostic safety netting). Some guidelines,
although not those from NICE, recommend that patients over
50 with new onset irritable bowel syndrome should undergo
colonoscopy.
Change in bowel habit and rectal bleeding
Change in bowel habit is a medical term, unused by patients. It
is not the same as diarrhoea or constipation, and the risk of
cancer is considerably higher when general practitioners’ record
“change of bowel habit” (3-4% in men aged >60) than when
they record diarrhoea (0.9-1.3%) or constipation (0.8%), in the
same age group.17 The most plausible explanation is that when
doctors record change in bowel habit they have included other
factors in their assessment and deem the total risk to be higher.
Arguably, all such patients warrant investigation.
Rectal bleeding is a classic symptom of colorectal cancer. In
primary care the risk of cancer ranges from 0.5% in women
aged less than 60 to 4.5% in men aged more than 80.17 The risk
is higher when diarrhoea is present or when local anal symptoms
such as pain, soreness, and itch are absent.18 A similar pattern
of higher risk with increasing age, multiple symptoms, and
absent perianal symptoms is seen in the referred population.19
The Association of Coloproctologists of Great Britain and
Ireland have developed a bowel symptom checker for the public
and for primary care (www.haveigotbowelcancer.com).
How is colorectal cancer investigated?
Complete examination of the large bowel by colonoscopy after
full bowel preparation remains the standard investigation for
patients suspected of having bowel cancer. Where colonoscopy
is incomplete (in around 11% of patients),20 it may be repeated,
or computed tomography colonography performed. Computed
tomography colonography has a similar identification rate for
cancer and polyps to that of colonoscopy, and both are superior
to barium enema.20 21 All the standard investigations have low
false negative rates, although persistent symptoms may require
reinvestigation.22
How is colorectal cancer managed?
National guidance on the management of colorectal cancer was
published in November 2011.23 Surgery, either open or
laparoscopic, is the primary treatment. Adjuvant treatments
include postoperative chemotherapy in patients with node
positive (Dukes’ stage C) results, and preoperative radiotherapy,
which reduces the risk of local recurrence in rectal cancer.
Metastases to the liver or lung may also be resected. Patients
presenting with large bowel obstruction can sometimes be
decompressed with an endoscopically placed stent, allowing
resection later.
We thank Eustacia Hamilton for help with the initial searches.
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Key points
• Patients with mild anaemia can still have colorectal cancer, even if their haemoglobin level is above the threshold recommended by
NICE for urgent investigation
• In people aged over 60, women with a haemoglobin concentration ≤110 g/L andmen ≤120 g/L and iron deficiency are worth investigating
for cancer
• Patients with a new diagnosis of irritable bowel syndrome should have their response to treatment monitored in case of misdiagnosis
• Doctors who record “change in bowel habit” rather than diarrhoea or constipation are potentially thinking of colorectal cancer and
further investigations should be considered
Contributors: WH performed the initial searches and drafted the first
version of the article. All three authors revised the article, adding
additional references. WH is the guarantor.
Competing interests. All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: WH has received
several research grants for studies on cancer diagnosis, including one
from Colonix, a commercial firm. He is the clinical lead for the current
revision of the NICE 2005 guidance. His contribution to this article is in
a personal capacity and is not to be interpreted as representing the view
of the Guideline Development Group or of NICE itself. He has received
travel support to give lectures and attend conferences, plus occasional
modest speaker’s fees, from conference organisers in the charitable
and educational sector, though none from commercial sources. MGC
is the national lead clinician for the Lapco National Training Programme
in Laparoscopic Colorectal Surgery. He is the chairman of external
affairs for the Association of Coloproctologists of Great Britain and
Ireland and a national peer review advisor for the
hepatopancreaticobiliary cancer peer review group. His contribution to
this article is in a personal capacity. He has received travel support to
give lectures and attend conferences, plus fees, from conference
organisers in the educational sector, and some from commercial sources
to lecture abroad on laparoscopic colorectal surgery from Olympus,
Johnson & Johnson and Covidien. GR is the Royal College of General
Practitioners clinical lead for cancer, a post part funded by Cancer
Research UK. He has received support for travel and conference
attendance, and payment for advisory services from Lilly, Almirall, and
Warner Chilcott. His contribution to this article is in a personal capacity.
All authors are members of the Bowel Cancer UK Medical Advisory
Board. No other relationships or activities that could appear to have
influenced the submitted work.
Provenance and peer review: Commissioned; externally peer reviewed.
Patient consent not required (patient anonymised, dead, or hypothetical).
1 Astin M, Griffin T, Neal RD, Rose P, Hamilton W. The diagnostic value of symptoms for
colorectal cancer in primary care: a systematic review. Br J Gen Pract 2011;61:e231-43.
2 Cancer Research UK. CancerStats key facts: bowel cancer. Cancer Research UK, 2012.
3 Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S, et al. Routes to
diagnosis for cancer—determining the patient journey using multiple routine data sets.
Br J Cancer 201;107:1220-6.
4 National Institute for Health and Clinical Excellence. Referral guidelines for suspected
cancer. NICE, 2005.
5 Hamilton W. Cancer diagnosis in primary care. Br J Gen Pract 2010;60:121-8.
6 Stapley S, Peters TJ, Sharp D, Hamilton W. The mortality of colorectal cancer in relation
to the initial symptom and to the duration of symptoms: a cohort study in primary care.
Br J Cancer 2006;95:1321-5.
7 Singh H, Daci K, Petersen LA, Collins C, Petersen NJ, Shethia A, et al. Missed
opportunities to initiate endoscopic evaluation for colorectal cancer diagnosis. Am J
Gastroenterol 2009;104:2543-54.
8 Domínguez-Ayala M, Díez-Vallejo J, Comas-Fuentes A. Missed opportunities in early
diagnosis of symptomatic colorectal cancer. Rev Esp Enfirm Dig 2012;104:343-9.
9 Damery S, Ryan R, Wilson S, Ismail T, Hobbs R, On behalf of the Improving Colorectal
Outcomes Group. Iron deficiency anaemia and delayed diagnosis of colorectal cancer:
a retrospective cohort study. Colorectal Dis 2011;13:e53-60.
10 Torring M, Frydenberg M, Hansen R, Olesen F, HamiltonW, Vedsted P. Time to diagnosis
and mortality in colorectal cancer: a cohort study in primary care. Br J Cancer
2011;104:934-40.
11 Thompson MR, Heath I, Swarbrick ET, Faulds Wood L, Ellis BG. Earlier diagnosis and
treatment of symptomatic bowel cancer: can it be achieved and how much will it improve
survival? Colorectal Dis 2011;13:6-16.
12 Masson S, Chinn DJ, Tabaqchali MA, Waddup G, Dwarakanath AD. Is anaemia relevant
in the referral and diagnosis of colorectal cancer? Colorectal Dis 2007;9:736-9.
13 Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng K, Marshall T. The importance of
anaemia in diagnosing colorectal cancer: a case-control study using electronic primary
care records. Br J Cancer 2008;98:323-7.
14 Sawhney MS, Lipato T, Nelson DB, Lederle FA, Rector TS, Bond JH. Should patients
with anemia and low normal or normal serum ferritin undergo colonoscopy? Am J
Gastroenterol 2007;102:82-8.
15 Hamilton W, Round A, Sharp D, Peters T. Clinical features of colorectal cancer before
diagnosis: a population-based case-control study. Br J Cancer 2005;93:399-405.
16 García Rodríguez L, Ruigómez A, Wallander M, Johansson S, Olbe L. Detection of
colorectal tumor and inflammatory bowel disease during follow-up of patients with initial
diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2000:35:306-11.
17 Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng KK, Marshall T. The risk of
colorectal cancer with symptoms at different ages and between the sexes: a case-control
study. BMC Med 2009;7:17.
18 Ellis BG, Thompson M. Factors identifying higher risk rectal bleeding in general practice.
Br J Gen Pract 2005;55:949-55.
19 Thompson MR, Perera R, Senapati A, Dodds S. Predictive value of common symptom
combinations in diagnosing colorectal cancer. Br J Surg 2007;94:1260-5.
20 Atkin W, Dadswell E, Wooldrage K, Kralj-Hans I, von Wagner C, Edwards R, et al.
Computed tomographic colonography versus colonoscopy for investigation of patients
with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial.
Lancet 2013; published online 14 Feb.
21 Halligan S, Wooldrage K, Dadswell E, Kralj-Hans I, von Wagner C, Edwards R, et al.
Computed tomographic colonography versus barium enema for diagnosis of colorectal
cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial.
Lancet 2013; published online 14 Feb.
22 Johnson CD, Chen M-H, Toledano AY, Heiken JP, Dachman A, Kuo MD, et al. Accuracy
of CT colonography for detection of large adenomas and cancers. N Engl J Med
2008;359:1207-17.
23 National Institute for Health and Clinical Excellence. Colorectal cancer: the diagnosis and
management of colorectal cancer: CG131. NICE, 2011.
Cite this as: BMJ 2013;346:f3172
© BMJ Publishing Group Ltd 2013
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f3172 doi: 10.1136/bmj.f3172 (Published 21 May 2013) Page 3 of 3
PRACTICE
